<DOC>
	<DOCNO>NCT01191944</DOCNO>
	<brief_summary>The objective trial evaluate non-inferiority pramipexole Extended release Immediate release 18 week primary efficacy endpoint ( Unified Parkinson 's Disease Rating Scale II+III ) Chinese PD patient concomitantly treat Levodopa .</brief_summary>
	<brief_title>Pramipexole Extended Release Versus Pramipexole Immediate Release 18 Weeks Chinese Parkinson 's Disease ( PD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female Chinese patient idiopathic Parkinson 's disease ( PD ) confirm least two follow sign : rest tremor , bradykinesia , rigidity . 2 . Parkinson 's disease diagnose least 2 year . 3 . Patients 30 year age old time diagnosis . 4 . Modified Hoehn Yahr stage 2 4 ontime . 5 . If patient treat standard control release Levodopa combine DopaDecarboxylaseinhibitor Levodopa combine DopaDecarboxylaseinhibitor/entacapone , dosage optimise accord investigator 's judgement , stable least 4 week prior baseline visit . 6 . If patient treat Levodopa combine DopaDecarboxylaseinhibitor motor fluctuation , 6 hour offtime every day wake hour ( document patient diary complete 2 consecutive day baseline visit ) . 7 . Patient willing able comply schedule visit , treatment plan , laboratory test study procedure ( particular , training , patient able recognise offtime ontime period wake hour record accurately patient diary ) . 8 . Signed informed consent obtain study procedure carry ( accordance International Conference HarmonisationGood Clinical Practice guideline local legislation ) . Exclusion criterion : Medical exclusion : 1 . Atypical parkinsonian syndrome due drug ( e.g. , metoclopramide , flunarizine ) , metabolic disorder ( e.g. , Wilson 's disease ) , encephalitis degenerative disease ( e.g. , progressive supranuclear palsy ) . 2 . Dementia , define MiniMental State Exam score &lt; 24 screen visit [ R962656 ] . 3 . Any psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) criterion could prevent compliance completion study and/or put patient risk he/she take part study . 4 . History psychosis , except history drug induce hallucination ( provide investigator considers participation trial would represent significant risk patient ) . 5 . History deep brain stimulation 6 . Clinically significant electrocardiogram abnormality screen visit , accord investigator 's judgement . 7 . Clinically significant hypotension ( i.e . supine systolic blood pressure &lt; 90 mmHg ) and/or symptomatic orthostatic hypotension ( i.e . clinical symptom orthostatic hypotension associate decline &gt; =20 mmHg systolic blood pressure decline &gt; = 10 mmHg diastolic blood pressure , one minute standing compare previous supine systolic diastolic blood pressure obtain 5 minute quiet rest ) screen baseline visit . 8 . Malignant melanoma history previously treat malignant melanoma . 9 . Any clinically significant disease , whether treat , could put patient risk could prevent compliance completion study . 10 . Pregnancy ( excluded urine pregnancy test screen visit ) breastfeeding . 11 . Sexually active female childbearing potential ( less 6 month postmenopausal surgically sterilise ) use medically approve method birth control ( i.e . oral contraceptive , intrauterine device , doublebarrier ) least one month prior screen visit throughout study period ( followup visit ) . 12 . Serum level Aspartate Aminotransferase , Alanine Aminotransferase , alkaline phosphatase total bilirubin &gt; 2 Upper Limit Normal ( screen lab test ) . 13 . Patients creatinine clearance &lt; 50 mL/min/1.73m2 ( estimate local lab / investigator use Modification Diet Renal Disease ( MDRD ) , calculate screen lab test )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>